Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma

Sonpavde, Guru; Pond, Gregory R.; Choueiri, Toni K.; Mullane, Stephanie A.; Niegisch, Günter; Albers, Peter; Necchi, Andrea; Lorenzo, Giuseppe Di; Buonerba, Carlo; Rozzi, Antonio; Matsumoto, Kazumasa; Lee, Jae‐Lyun; Kitamura, Hiroshi; Kume, Haruki; Bellmunt, Joaquim

doi:10.1016/j.eururo.2015.07.042

Cited by 60 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7172] A pooled analysis of trials on taxane-based salvage chemotherapy suggested a survival benefit with combination regimens, albeit with more toxicity. [73] In platinum refractory patients, nanoparticle albumin-bound (nab) paclitaxel achieved a remarkable ORR of 27.7% with 1 of 48 patients achieving a CR and was well tolerated. [74] Cabazitaxel in Phase 2 studies has shown 5% ORR but with increased toxicity and is currently being trialed as the second-line agent.…”

Section: Methodsmentioning

confidence: 99%

Systemic therapy in bladder cancer

Pinto

2017

Indian J Urol

View full text Add to dashboard Cite

Systemic chemotherapy is essential for the management of muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer (BCa). Neoadjuvant chemotherapy is key to the management of MIBC with many cisplatin-based regimens. Adjuvant chemotherapy may be considered for selected patients who did not receive neoadjuvant therapy. Systemic chemotherapy with radiotherapy is a critical component of a trimodal bladder-preserving approach and is superior to radiotherapy alone. Cisplatin-based chemotherapy has been the mainstay for metastatic BCa. Immunotherapy in the form of checkpoint inhibitors is a promising new drug for the treatment of BCa. Molecular characterization of each individual BCa is likely to lead to a target-directed therapeutic revolution.

show abstract

Section: Methodsmentioning

confidence: 99%

Systemic therapy in bladder cancer

Pinto

2017

Indian J Urol

View full text Add to dashboard Cite

show abstract

“…Despite some differences in outcomes may be acknowledged between the single-agent or combination therapies administered in the salvage setting, the latter may be used in a minority of cases who are preserving an adequate performance status. Globally, the median PFS and OS estimates approximate 3 and 6 months, respectively, with a few exceptions for patients having favorable prognostic factors Sonpavde et al, 2015a). Some recommendations for patient eligibility and stratification of patients in clinical trials in the salvage setting have been proposed, and indeed improvements in the stratification of outcome in the second-line setting have been achieved as well, with enhanced prognostic grouping systems that are now available (Sonpavde et al, 2015b;Sonpavde et al, 2014).…”

Section: Immunotherapy For Urothelial Bladder Carcinomamentioning

confidence: 97%

Immunotherapy advances in uro-genital malignancies

Ratta

Zappasodi

Raggi

et al. 2016

Critical Reviews in Oncology/Hematology

Self Cite

View full text Add to dashboard Cite

“…Considering the mechanism mediating the acquisition of the resistant phenotype to chemotherapeutic agents, second-line regimens are not likely to include agents integrated into the first-line chemotherapy. Nowadays, most institutions in Japan administer paclitaxel-based chemotherapy (as single agents or combinations) to patients with advanced UC refractory to first-line GC therapy [16]. In a large retrospective study, combination chemotherapy was possibly significantly associated with improved OS compared with single-agent therapy (HR 0.60, P = 0.001) [16].…”

Section: Introductionmentioning

confidence: 99%

“…Nowadays, most institutions in Japan administer paclitaxel-based chemotherapy (as single agents or combinations) to patients with advanced UC refractory to first-line GC therapy [16]. In a large retrospective study, combination chemotherapy was possibly significantly associated with improved OS compared with single-agent therapy (HR 0.60, P = 0.001) [16]. When pembrolizumab therapy is used as a second-line therapy, taxane-including regimens may be used as third-line therapies.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in medical therapy for metastatic urothelial cancer

2018

View full text Add to dashboard Cite

Cytotoxic chemotherapy has been the mainstay of medical therapy for metastatic urothelial cancer. Currently, the gemcitabine/cisplatin regimen is widely used worldwide as the standard first-line medical treatment. Very recently, in 2017, pembrolizumab, a highly selective, humanized monoclonal IgG4κ isotype antibody against programmed death 1, was approved as a second-line treatment to be used after platina-based chemotherapy for metastatic urothelial cancer in Japan. Based on its promising anti-tumor efficacy and manageable safety profile as demonstrated in the phase III KEYNOTE-045 trial, pembrolizumab therapy is expected to be rapidly introduced for treating metastatic urothelial cancer in clinical practice. The paradigm of medical treatment for patients with metastatic UC is dramatically changing through the introduction of this and other immune-checkpoint inhibitors. In this article, we provide a brief overview of these immune-checkpoint inhibitors and a comprehensive summary of the use of cytotoxic chemotherapy for metastatic urothelial cancer, including ongoing clinical trials.

show abstract

Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma

Cited by 60 publications

References 24 publications

Systemic therapy in bladder cancer

Systemic therapy in bladder cancer

Immunotherapy advances in uro-genital malignancies

Recent advances in medical therapy for metastatic urothelial cancer

Contact Info

Product

Resources

About